Significance of tribbles 3 expression in the carcinogenesis of colonic polyps

doi:10.3877/cma.j.issn.1674-0793.2020.06.009

Abstract

Abstract:

Objective

To study the expression of tribbles 3 (TRIB3) in the carcinogenesis of colonic polyps and its clinical significance.

Methods

From January 2017 to January 2019, 85 colonic polyps (polyps group) and 87 colonic cancer tissue samples (colon cancer group) from Hainan People’s Hospital were collected, and 102 normal colonic tissues were taken as control (normal group). The expression degrees of TRIB3 in the three groups were determined by immunohistochemistry, and the relationship between the expression level and clinicopathological parameters was analyzed.

Results

The positive expression rates of TRIB3 in normal group, polyps group and colon cancer group were 15.69% (16/102), 60.00% (51/85) and 95.74% (90/94), respectively. There was significant difference among the three groups (χ2=128.010, P<0.001). The expression level of TRIB3 was related to pathological classification in colonic polyps (χ2=12.650, P=0.013), and it was related to clinical stage, lymph node metastasis, distant metastasis and differentiation degree in colon cancer (all P<0.05).

Conclusion

The expression of TRIB3 is graduallyup-regulated during the carcinogenesis of colon polyps, which is related to the clinical stage, metastasis situation and differentiation of colon cancer, and is expected to become a clinical indicator for detecting colon polyps carcinogenesis.

Key words: Tribbles 3, Colonic polyps, Canceration, Immunohistochemistry

Manni Cai, Xiangyang Han, Yongdong Huang, Zhoutao He, Yuxuan Wang, Dongyan Zhang, Chao Yan, Ning Liu. Significance of tribbles 3 expression in the carcinogenesis of colonic polyps[J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(06): 439-442.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2020.06.009

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2020/V14/I06/439

Figures/Tables 4

References 15

[1]	房玉海. 结肠息肉发病相关危险因素临床研究进展[J]. 中国处方药, 2016, 14(9): 22-23.
[2]	安俊平, 刘彬, 师艾丽, 等. 结肠息肉的临床病理特征及其与癌变的相关分析[J]. 中国医师杂志, 2017, 19(7): 1035-1037, 1042.
[3]	舒晴, 赵素芳, 焦璐, 等. 结肠息肉癌变的相关危险因素及内镜治疗随访结果分析[J]. 现代消化及介入诊疗, 2016, 21(1): 24-27.
[4]	Hsiao KY, Lin YC, Gupta SK, et al. Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis[J]. Cancer Res, 2017, 77(9): 2339-2350.
[5]	Butcher L, Ahluwalia M, Örd T, et al. Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis[J]. Sci Rep, 2017, 7(1): 6684.
[6]	Li K, Wang F, Cao WB, et al. TRIB3 promotes APL progression through stabilization of the oncoprotein PML-RARα and inhibition of p53-mediated senescence[J]. Cancer Cell, 2017, 31(5): 697-710.e7.
[7]	Su J, Yan Y, Qu J, et al. Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-κB pathway[J]. Oncol Rep, 2017, 37(3): 1565-1572.
[8]	王洋, 金忠芹, 武庆斌. 儿童结肠息肉临床诊治分析[J]. 临床儿科杂志, 2017, 35(11): 860-863.
[9]	吴义娟, 陈现亮, 吕卓, 等. MTA1、RECK在结肠息肉癌变过程中的表达及意义[J]. 中国老年学杂志, 2018, 38(16): 4021-4023.
[10]	马敏敏. 结肠息肉患者手术前后的流程化沟通实践[J]. 护理学报, 2017, 24(6): 20-22.
[11]	董少婷. TRIB3基因的研究进展[J]. 中国基层医药, 2016, 22(4): 625-626, 627.
[12]	Zhang C, Hong FF, Wang CC, et al. TRIB3 inhibits proliferation and promotes osteogenesis in hBMSCs by regulating the ERK1/2 signaling pathway[J]. Sci Rep, 2017, 7(1): 10342.
[13]	Dong S, Xia J, Wang H, et al. Overexpression of TRIB3 promotes angiogenesis in human gastric cancer[J]. Oncol Rep, 2016, 36(4): 2339-2348.
[14]	周玉, 刘国涛, 卢增珍, 等. TRIB3基因和TLR4蛋白在糖尿病血管病变中的表达及桃仁干预作用[J]. 中国中西医结合外科杂志, 2018, 24(6): 733-737.
[15]	李珂, 王凤, 曹文斌, 等. TRIB3通过维持原癌蛋白PML-RARα的稳定性、抑制p53介导的抗癌作用，促进急性早幼粒白血病的发病及疾病进展[J]. 科学新闻, 2018, 546(4): 52.

组别	例数	-	＋	＋＋	＋＋＋	阳性
正常组	102	86(84.31)	13(12.75)	3(2.94)	0(0.00)	16(15.69)
息肉组	85	34(40.00)	4(4.71)	35(12.94)	12(41.18)	51(60.00)^a
结肠癌组	94	4(4.26)	16(17.02)	31(32.98)	43(45.74)	90(95.74)^b

组别	例数	-	＋	＋＋	＋＋＋	阳性
正常组	102	86(84.31)	13(12.75)	3(2.94)	0(0.00)	16(15.69)
息肉组	85	34(40.00)	4(4.71)	35(12.94)	12(41.18)	51(60.00)^a
结肠癌组	94	4(4.26)	16(17.02)	31(32.98)	43(45.74)	90(95.74)^b

病理特征		例数	低表达(38例)	高表达(47例)	χ²值	P值
年龄(岁)					0.097	0.755
	< 45	34	14(41.18)	20(58.82)
	≥45	51	24(47.06)	27(52.94)
性别					0.001	0.977
	男	46	21(45.65)	25(54.35)
	女	39	17(43.59)	22(56.41)
息肉位置					2.100	0.717
	乙状结肠	30	14(46.67)	16(53.33)
	降结肠	19	10(52.63)	9(47.37)
	横结肠	17	7(41.18)	10(58.82)
	升结肠	11	3(27.27)	8(72.73)
	回盲部	8	3(37.50)	5(62.50)
数目					0.013	0.910
	单发	52	24(46.15)	28(73.08)
	多发	33	14(42.42)	19(57.58)
蒂形态					0.173	0.677
	无	30	12(40.00)	18(60.00)
	有	55	26(47.27)	29(57.73)
黏膜状态					0.150	0.997
	光滑	24	10(41.67)	14(58.33)
	粗糙	18	8(44.44)	10(55.56)
	糜烂	26	12(46.15)	14(53.85)
	溃疡	17	8(47.06)	9(52.94)
息肉直径(cm)					1.988	0.159
	≤1	30	17(56.67)	13(43.33)
	> 1	55	21(38.18)	34(61.82)
分叶					0.003	0.957
	无	68	30(44.12)	38(55.88)
	有	17	8(47.06)	9(52.94)
病理组织学					12.650	0.013
	腺瘤性	32	12(37.50)	20(62.50)
	炎性	26	9(34.62)	17(65.38)
	增生性	15	6(40.00)	9(60.00)
	错构瘤性	10	9(90.00)	1(10.00)
	其他	2	2(100.00)	0(0)
不典型增生					0.366	0.985
	无	52	24(46.15)	28(53.85)
	低度	16	7(43.75)	9(56.25)
	中度	11	5(45.45)	6(54.55)
	重度	6	2(33.33)	4(66.67)

病理特征		例数	低表达(38例)	高表达(47例)	χ²值	P值
年龄(岁)					0.097	0.755
	< 45	34	14(41.18)	20(58.82)
	≥45	51	24(47.06)	27(52.94)
性别					0.001	0.977
	男	46	21(45.65)	25(54.35)
	女	39	17(43.59)	22(56.41)
息肉位置					2.100	0.717
	乙状结肠	30	14(46.67)	16(53.33)
	降结肠	19	10(52.63)	9(47.37)
	横结肠	17	7(41.18)	10(58.82)
	升结肠	11	3(27.27)	8(72.73)
	回盲部	8	3(37.50)	5(62.50)
数目					0.013	0.910
	单发	52	24(46.15)	28(73.08)
	多发	33	14(42.42)	19(57.58)
蒂形态					0.173	0.677
	无	30	12(40.00)	18(60.00)
	有	55	26(47.27)	29(57.73)
黏膜状态					0.150	0.997
	光滑	24	10(41.67)	14(58.33)
	粗糙	18	8(44.44)	10(55.56)
	糜烂	26	12(46.15)	14(53.85)
	溃疡	17	8(47.06)	9(52.94)
息肉直径(cm)					1.988	0.159
	≤1	30	17(56.67)	13(43.33)
	> 1	55	21(38.18)	34(61.82)
分叶					0.003	0.957
	无	68	30(44.12)	38(55.88)
	有	17	8(47.06)	9(52.94)
病理组织学					12.650	0.013
	腺瘤性	32	12(37.50)	20(62.50)
	炎性	26	9(34.62)	17(65.38)
	增生性	15	6(40.00)	9(60.00)
	错构瘤性	10	9(90.00)	1(10.00)
	其他	2	2(100.00)	0(0)
不典型增生					0.366	0.985
	无	52	24(46.15)	28(53.85)
	低度	16	7(43.75)	9(56.25)
	中度	11	5(45.45)	6(54.55)
	重度	6	2(33.33)	4(66.67)

病理特征		例数	低表达(20例)	高表达(74例)	χ²值	P值
年龄(岁)					0.068	0.795
	< 45	40	8(20.00)	32(80.00)
	≥45	54	12(22.22)	42(77.78)
性别					0.013	0.910
	男	53	11(20.75)	42(79.25)
	女	41	9(21.95)	32(78.05)
浸润程度					0.104	0.748
	肌层下	21	5(23.81)	16(76.19)
	浆膜下	73	15(20.55)	58(79.45)
临床分期					9.163	0.002
	Ⅰ~Ⅱ	32	13(40.63)	19(59.38)
	Ⅲ~Ⅳ	62	7(11.29)	55(88.71)
淋巴转移					27.653	<0.001
	有	28	16(57.14)	12(42.86)
	无	66	4(6.06)	62(93.94)
肿瘤直径(cm)					0.361	0.548
	≤5	36	6(16.67)	30(83.33)
	> 5	58	14(24.14)	44(75.86)
远处转移					4.407	0.036
	有	64	18(28.13)	46(71.88)
	无	30	2(6.67)	28(93.33)
大体类型					2.920	0.232
	隆起型	20	6(30.00)	14(70.00)
	溃疡型	56	11(19.64)	45(80.36)
	浸润型	18	7(38.89)	11(61.11)
分化程度					11.730	0.001
	低	19	10(52.63)	9(47.37)
	中、高	75	10(13.33)	65(86.67)

Please choose a citation manager

Content to export